CN112961119A - 一种非布司他杂质的制备方法 - Google Patents
一种非布司他杂质的制备方法 Download PDFInfo
- Publication number
- CN112961119A CN112961119A CN202110079668.XA CN202110079668A CN112961119A CN 112961119 A CN112961119 A CN 112961119A CN 202110079668 A CN202110079668 A CN 202110079668A CN 112961119 A CN112961119 A CN 112961119A
- Authority
- CN
- China
- Prior art keywords
- febuxostat
- methylthiazole
- impurity
- formyl
- hydroxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 229960005101 febuxostat Drugs 0.000 title claims abstract description 23
- 239000012535 impurity Substances 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims abstract description 22
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 9
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 235000019253 formic acid Nutrition 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 claims description 3
- XHTJJFYEXYGKAH-UHFFFAOYSA-N 2-(2-methylpropoxy)-5-(4-methyl-1,3-thiazol-2-yl)benzaldehyde Chemical compound C1=C(C=O)C(OCC(C)C)=CC=C1C1=NC(C)=CS1 XHTJJFYEXYGKAH-UHFFFAOYSA-N 0.000 claims description 3
- CYDHRNRXVSNMCU-UHFFFAOYSA-N 2-hydroxy-5-(4-methyl-1,3-thiazol-2-yl)benzaldehyde Chemical compound CC1=CSC(C=2C=C(C=O)C(O)=CC=2)=N1 CYDHRNRXVSNMCU-UHFFFAOYSA-N 0.000 claims description 3
- WGZUNRFJOVLPQO-UHFFFAOYSA-N 2-hydroxy-5-(4-methyl-1,3-thiazol-2-yl)benzonitrile Chemical compound Cc1csc(n1)-c1ccc(O)c(c1)C#N WGZUNRFJOVLPQO-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004280 Sodium formate Substances 0.000 claims description 3
- NJRGQNNSIAFIJC-UHFFFAOYSA-N ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate Chemical compound CC1=C(C(=O)OCC)SC(C=2C=C(C=O)C(O)=CC=2)=N1 NJRGQNNSIAFIJC-UHFFFAOYSA-N 0.000 claims description 3
- LOCYSKNNFCGDTR-UHFFFAOYSA-N ethyl 2-(4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate Chemical compound CC1=C(C(=O)OCC)SC(C=2C=CC(O)=CC=2)=N1 LOCYSKNNFCGDTR-UHFFFAOYSA-N 0.000 claims description 3
- AIQMFFCWDAIGNV-UHFFFAOYSA-N ethyl 2-[3-formyl-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylate Chemical compound CC1=C(C(=O)OCC)SC(C=2C=C(C=O)C(OCC(C)C)=CC=2)=N1 AIQMFFCWDAIGNV-UHFFFAOYSA-N 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 claims description 3
- 235000019254 sodium formate Nutrition 0.000 claims description 3
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 abstract description 4
- 230000029936 alkylation Effects 0.000 abstract description 2
- 238000005804 alkylation reaction Methods 0.000 abstract description 2
- 238000007333 cyanation reaction Methods 0.000 abstract description 2
- 238000007037 hydroformylation reaction Methods 0.000 abstract description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 2
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 2
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- BPCINBSGQOXTMS-UHFFFAOYSA-N phenol;sulfamide Chemical compound NS(N)(=O)=O.OC1=CC=CC=C1 BPCINBSGQOXTMS-UHFFFAOYSA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
本发明公开了一种非布司他杂质的制备方法,原料在三氟乙酸与乌洛托品条件下进行醛基化、氰基化和烷基化三步反应,每步反应收率90%以上得到非布司他杂质的目标产品。本发明采用上述一种非布司他杂质的制备方法,操作简单,可控性强,产品收率高。
Description
技术领域
本发明涉及化学制药技术领域,特别是涉及一种非布司他杂质的制备方法。
背景技术
非布司他(Febuxostat)化学名为2-(3-氰基-4-异丁氧苯基)-4-甲基噻唑 -5-羧酸,是一种非嘌呤型黄嘌呤氧化酶/黄嘌呤脱氢酶(XO)的选择性抑制剂,具有很高的选择性和更强的活性,不良反应少,适用于治疗慢性高尿酸血症,缓解痛风,其疗效优于别嘌醇治疗痛风的效果。
但是,非布司他结构式较为复杂,合成路线步骤长,该状况导致非布司他API中潜在杂质多。合成出该系列杂质对照品,对非布司他的质量研究有重要的意义。
发明内容
本发明的目的是提供一种非布司他杂质的制备方法,操作简单,可控性强,产品收率高。
为实现上述目的,本发明提供了一种非布司他杂质的制备方法,非布司他杂质合成反应式如下:
优选的,2-(3-甲酰基-4-羟基苯基)-4-甲基噻唑合成反应式如下:
将2-(4-羟基苯基)-4-甲基噻唑-5-羧酸乙酯置于三口瓶中,加入三氟乙酸(TFA),加入乌洛托品(HMT),加热至回流,反应52小时,TLC(氯仿: 乙醇=14:1)检测控制反应终点;反应毕,搅拌下稀释到水中,析出固体,搅拌,过滤得固体(中间体Ⅰ),收率98.0-99.0%。
优选的,2-(3-氰基-4-羟基苯基)-4-甲基噻唑合成反应式如下:
将2-(3-甲酰基-4-异丁氧基苯基)-4-甲基噻唑-5-羧酸乙酯、盐酸羟胺 (NH2OH·HCl)和甲酸钠置于三口瓶中,加入甲酸(HCOOH),加热到100℃,反应22-30小时,TLC(氯仿:乙酯=20:1),检测反应至原料点消失,停止反应;反应液冷却到室温,搅拌下缓慢稀释到水中,析出固体,搅拌,过滤得固体(中间体Ⅱ),收率90-96%。
优选的,2-(3-甲酰基-4-异丁氧基苯基)-4-甲基噻唑合成反应式如下:
将2-(3-甲酰基-4-羟基苯基)-4-甲基噻唑-5-羧酸乙酯(中间体Ⅱ)置于三口瓶中,加入二甲基甲酰胺(DMF),然后加入无水碳酸钾、溴代异丁烷、碘化钾,加热到65-75℃,反应8小时;TLC(氯仿:乙酸乙酯=16:1)检测控制反应终点,冷却,搅拌下稀释到水中,过滤得固体(目标产物),收率 90.0-95.0%。
因此,本发明采用上述一种非布司他杂质的制备方法,原料在三氟乙酸与乌洛托品条件下进行醛基化、氰基化和烷基化3步反应,每步反应收率90%以上得到目标产品非布司他杂质。
本发明的制备方法,具有如下技术优势:
(1)本发明以便宜易得的对羟基苯硫酰胺为原料,大大降低了产品成本;
(2)本发明在合成过程中无高温高压反应,通过温和易操作的合成方法,实现所有步骤都温和可控,操作简单,可控性强;
(3)本发明的合成方法,产品收率高,纯度达到99%以上。
下面通过实施例,对本发明的技术方案做进一步的详细描述。
具体实施方式
下面对本发明的实施方式做进一步的说明。
一种非布司他杂质的制备方法,非布司他杂质的合成反应式如下:
其中,(1)2-(3-甲酰基-4-羟基苯基)-4-甲基噻唑的制备
反应时,将171g 2-(4-羟基苯基)-4-甲基噻唑-5-羧酸乙酯置于2000mL三口瓶中,加入1500mL三氟乙酸(TFA),加入乌洛托品(HMT)162g,加热至回流,反应52小时,TLC(氯仿:乙醇=14:1)检测控制反应终点。反应毕,搅拌下稀释到25L水中,析出固体,搅拌,过滤得固体168g,收率98.0%。
(2)2-(3-氰基-4-羟基苯基)-4-甲基噻唑的制备
反应时,将580g 2-(3-甲酰基-4-异丁氧基苯基)-4-甲基噻唑-5-羧酸乙酯 (中间体IV)、盐酸羟胺(NH2OH·HCL)176g和甲酸钠15g置于10L三口瓶中,加入4400ml甲酸(HCOOH),加热到100℃,反应约22-30小时,TLC (氯仿:乙酯=20:1),检测反应至原料点消失,停止反应。反应液冷却到室温,搅拌下缓慢稀释到4400ml水中,析出固体,搅拌,过滤得固体(中间体 V)472.2g,收率90%。
(3)2-(3-甲酰基-4-异丁氧基苯基)-4-甲基噻唑的制备
反应时,将752g 2-(3-甲酰基-4-羟基苯基)-4-甲基噻唑-5-羧酸乙酯(中间体2)置于10L三口瓶中,加入5984ml二甲基甲酰胺(DMF),然后加入无水碳酸钾2288g、溴代异丁烷1540g、碘化钾152g,加热到65-75℃,反应8 小时。TLC(氯仿:乙酸乙酯=16:1)检测控制反应终点,冷却,搅拌下稀释到5500ml水中,过滤得固体(中间体Ⅳ)861.4g,收率90.0%。
因此,本发明采用上述一种非布司他杂质的制备方法,操作简单,可控性强,产品收率高。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进,这些改进也应视为本发明的保护范围。
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110079668.XA CN112961119A (zh) | 2021-01-21 | 2021-01-21 | 一种非布司他杂质的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110079668.XA CN112961119A (zh) | 2021-01-21 | 2021-01-21 | 一种非布司他杂质的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112961119A true CN112961119A (zh) | 2021-06-15 |
Family
ID=76271345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110079668.XA Pending CN112961119A (zh) | 2021-01-21 | 2021-01-21 | 一种非布司他杂质的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112961119A (zh) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101921243A (zh) * | 2010-08-14 | 2010-12-22 | 青岛黄海制药有限责任公司 | 一种制备2-(3-甲酰基-4-异丁氧基苯基)-4-甲基-1,3噻唑-5-羧酸乙酯的方法 |
WO2012014994A1 (ja) * | 2010-07-30 | 2012-02-02 | ダイトーケミックス株式会社 | ナフタレン誘導体 |
WO2012131590A1 (en) * | 2011-03-31 | 2012-10-04 | Sandoz Ag | An improved process for preparation of febuxostat and its polymorphic crystalline form c thereof |
CN106279041A (zh) * | 2016-08-16 | 2017-01-04 | 四川思睿博生物科技有限公司 | 苯基嘧啶衍生物及其制备方法和用途 |
CN106366048A (zh) * | 2016-08-23 | 2017-02-01 | 魏成功 | 一种控制非布司他中间体杂质的方法 |
CN110642804A (zh) * | 2019-10-17 | 2020-01-03 | 武汉光谷亚太医药研究院有限公司 | 一种非布司他的某个特定杂质的制备方法 |
CN110878064A (zh) * | 2019-11-06 | 2020-03-13 | 武汉光谷亚太医药研究院有限公司 | 一种非布司他的某个特定杂质的高收率合成方法 |
CN111303071A (zh) * | 2020-01-08 | 2020-06-19 | 武汉伯睿科医药科技有限公司 | 一种非布司他杂质的合成方法 |
-
2021
- 2021-01-21 CN CN202110079668.XA patent/CN112961119A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012014994A1 (ja) * | 2010-07-30 | 2012-02-02 | ダイトーケミックス株式会社 | ナフタレン誘導体 |
CN101921243A (zh) * | 2010-08-14 | 2010-12-22 | 青岛黄海制药有限责任公司 | 一种制备2-(3-甲酰基-4-异丁氧基苯基)-4-甲基-1,3噻唑-5-羧酸乙酯的方法 |
WO2012131590A1 (en) * | 2011-03-31 | 2012-10-04 | Sandoz Ag | An improved process for preparation of febuxostat and its polymorphic crystalline form c thereof |
CN106279041A (zh) * | 2016-08-16 | 2017-01-04 | 四川思睿博生物科技有限公司 | 苯基嘧啶衍生物及其制备方法和用途 |
CN106366048A (zh) * | 2016-08-23 | 2017-02-01 | 魏成功 | 一种控制非布司他中间体杂质的方法 |
CN110642804A (zh) * | 2019-10-17 | 2020-01-03 | 武汉光谷亚太医药研究院有限公司 | 一种非布司他的某个特定杂质的制备方法 |
CN110878064A (zh) * | 2019-11-06 | 2020-03-13 | 武汉光谷亚太医药研究院有限公司 | 一种非布司他的某个特定杂质的高收率合成方法 |
CN111303071A (zh) * | 2020-01-08 | 2020-06-19 | 武汉伯睿科医药科技有限公司 | 一种非布司他杂质的合成方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2598494B1 (en) | Improved process for the preparation of febuxostat | |
WO2011141933A2 (en) | Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts | |
WO2012131590A1 (en) | An improved process for preparation of febuxostat and its polymorphic crystalline form c thereof | |
US20130317234A1 (en) | Process for Preparation of Intermediates of Bendamustine | |
CN109553550B (zh) | 一种合成二氢燕麦生物碱的方法 | |
CN112961118A (zh) | 一种非布司他脱羧杂质的合成方法 | |
CA2606799C (en) | Process for synthesis of proton pump inhibitors | |
CN112961119A (zh) | 一种非布司他杂质的制备方法 | |
US20130172571A1 (en) | Process to prepare ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate | |
CN109912531B (zh) | 高纯度非布司他的制备方法 | |
CN103588765A (zh) | 阿齐沙坦酯或其盐的合成方法及其中间体和中间体的合成方法 | |
CN111499593A (zh) | 非布司他的合成工艺 | |
CN104402865B (zh) | 一种埃索美拉唑镁杂质d的制备方法 | |
CN108129303A (zh) | 一种r-(+)-2-(4-羟基苯氧基)丙酸甲酯的制备方法 | |
CN109265455B (zh) | 一种达沙替尼的制备方法 | |
US8129536B2 (en) | Method for the purification of lansoprazole | |
EP3312174B1 (en) | Method for preparing trityl candesartan | |
US3947464A (en) | Salts of phenylpropanolamine with thiazolidine carboxylic acids | |
US5516934A (en) | Process for producing mono-P-nitrobenzyl malonate | |
CN112521315B (zh) | 一种利多卡因降解杂质的制备方法 | |
KR900006556B1 (ko) | 2-구아니디노티아졸 유도체의 제조방법 | |
CN108822057B (zh) | 一种ae活性酯的合成方法 | |
WO2011012965A1 (en) | Improved process for preparation of ceftriaxone disodium hemiheptahydrate | |
CN109776448B (zh) | 一种非布司他a晶型的制备方法 | |
CN111646953A (zh) | 一种合成利托那韦的新方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210615 |